Q&A With Gerald Smetana, MD, from Beth Israel Deaconess Medical Center: Discussing Rivaroxaban's Newest Approvals in Primary Care

Rivaroxaban, also known as Xarelto has been on the market for many years but was recently approved for use in patients with DVT and pulmonary embolism.

Rivaroxaban, also known as Xarelto has been on the market for many years but was recently approved for use in patients with DVT and pulmonary embolism.

Gerald Smetana, MD, from Beth Israel Deaconess Medical Center discussed how the approval can benefit patients during the American College of Physicians Internal Medicine Meeting in Boston. Smetana said one of the main points about the new approval is that unlike warfarin, patients on rivaroxaban do not require monitoring.